Analyst Reco. NeuroPace, Inc.

Equities

NPCE

US6412881053

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
13.39 ^USD	+3.08%		-4.22%	+29.87%

03-15	North American Morning Briefing : Inflation -2-	DJ
03-14	Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16	03-14	MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating	03-12	MT
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating	02-22	MT
Leerink Partners Initiates NeuroPace at Outperform Rating With $22 Price Target	01-30	MT
Morgan Stanley Adjusts NeuroPace Price Target to $9 From $8, Maintains Equal Weight Rating	12-04	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $8 From $6, Maintains Equalweight Rating	11-14	MT
Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target	11-10	MT
Wells Fargo Adjusts NeuroPace Price Target to $9 From $6, Maintains Equal Weight Rating	04/10/23	MT
Morgan Stanley Upgrades NeuroPace to Equalweight From Underweight, Adjusts Price Target to $6 From $5	24/08/23	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $4.50 From $2.50, Maintains Underweight Rating	03/03/23	MT
Lake Street Initiates NeuroPace at Buy With $10 Price Target	22/02/23	MT
Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating	06/01/23	MT
Morgan Stanley Adjusts NeuroPace's Price Target to $3.50 from $5.50, Maintains Underweight Rating	11/10/22	MT
Wells Fargo Adjusts NeuroPace's Price Target to $6 from $9, Keeps Equalweight Rating	13/05/22	MT
Morgan Stanley Lowers NeuroPace's Price Target to $6 From $9, Maintains Underweight Rating	13/05/22	MT
Wolfe Research Starts NeuroPace at Outperform With $13 Price Target	06/04/22	MT
Wells Fargo Adjusts NeuroPace's Price Target to $9 from $11, Keeps Equalweight Rating	11/03/22	MT
SVB Leerink Adjusts NeuroPace's Price Target to $12 from $15, Keeps Outperform Rating	11/03/22	MT
Morgan Stanley Lowers Price Target for NeuroPace to $9 From $12, Maintains Underweight Rating	11/03/22	MT
JPMorgan Lowers Price Target for NeuroPace to $15 From $24, Maintains Overweight Rating	11/03/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NeuroPace, Inc.

Equities

NPCE

US6412881053

Analyst Reco.

Filters